Study | Study design & period | Location | No | Age | M | F | Primary pathology | Radiation | RN Diagnosis | RT to RN Diagnosis | RT to BV Tx | BV dosage | No. of cycles | Follow Up |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wang, et al. (2012) [50] | Retrospective Mar 2010 - Jan 2012 | Huashan Hospital, Fudan University, Shanghai, China | 5 | 65 | 4 | 1 | Colon 3 Lung 2 | EBRT/SRS/FSRT | MRI, MRS, PET | 4.6 | 7.5 mg/kg q2 week | 2–6 | 6 | |
Boothe, et al. (2013) [51] | Retrospective 3-year | Memorial Sloan- Kettering Cancer Center, New York, USA | 11 | 58 | 4 | 7 | Breast 5 NSCLC 6 | WBRT/SRS | MRI, biopsy, PET | 12.4 | 59.6 days | 7.5 mg/kg q3w (1) 10 mg/kg q2w (8) 15 mg/kg q4/6w (2) | 6 | 3.3 |
Furuse, et al. (2013) [52] | Retrospective Jan 2009 - Oct 2010 | Osaka Medical College, Takatsuki, Osaka, Japan | 3 | 62 | 1 | 2 | Unknown | SRS | MRI, MET-PET | 11 (median) | 5 mg/kg q2w | 3 | 14.4 | |
Yonezawa, et al. (2014) [53] | Prospective Nonrandomized Jun 2010 - Sep 2011 | Kizawa Memorial Hospital, Minokamo, Japan | 2 | 52.5 | 1 | 1 | Lung | WBRT/SRS/SRT | MRI, MET-PET | 19 | 5 mg/kg q2w | 6 | ||
Sadraei, et al. (2015) [54] | Retrospective Jul 2007 - Jun 2012 | Cleveland Clinic, Cleveland, Ohio, USA | 17 | 55.7 | 5 | 12 | lung (9), breast (4), rectal (1), melanoma (1), NSTC (1), FT (1)), | WBRT/SRS | MRI, PET, biopsy | 16.9 10.1 | 5/7.5/10/15 mg/kg q2/3w | 6 | 8 | |
Zhuang, et al. (2015) [55] | Retrospective Jun 2011 - Dec 2014 | Tianjin Cancer Hospital, Tianjin, China | 14 | 56 | 6 | 8 | Lung 11, Breast 1, Lymphoma 1, Gastric cancer 1 | RT | MRI, PET, pathology | 5 mg/kg q3-4w | 3 | 12 | ||
Xiang-Pan, L., et al. (2015) [49] | Retrospective | Wuhan, China | 1 | 60 | 1 | Lung | WBRT/SRS | MRI | 12 | 7.5 mg/kg q3w | 2 | |||
Alessandretti, et al. (2013) [48] | Retrospective | Hospital São José, São Paulo, Brazil | 2 | 49.5 | 2 | Melanoma | WBRT/SRS | MRI | 11.5 | 5,7.5 mg/kg q6/4w | ||||
Zhuang, et al. (2019) [33] | Prospective II CT Dec 2016 - Feb 2019 | Tianjin Cancer Hospital, Tianjin, China | 21 | 55 (median, range 43–70) | 11 | 10 | Lung 17 Breast 2 Kidney cancer 2 | SRT | MRI | 17.6 | 1 mg/kg q3w | 3 | 22.7 | |
Tanigawa, et al. (2019) [56] | Retrospective | Kagoshima University, Kagoshima, Japan | 4 | 61.25 | 2 | 2 | Lung | STI (stereotactic irradiation) | MRI | 7.75 | 15 mg/kg q3–4w | |||
Ma, et al. (2017) [57] | Retrospective | Zhejiang University, Hangzhou, China | 2 | 62 | 2 | NSCLC | SRS | MRI | 6.5 | 5 mg/kg q2w/7.5 mg/kg q3w | 2.5 | 9 | ||
Glitza, I. et al. (2017) [58] | Retrospective | The University of Texas MD Anderson Cancer and Baylor College of Medicine, Houston, Texas, USA | 7 | 57 | 5 | 2 | Melanoma | SRS/WBRT | Surgery, MRI, pathology | 8.14 | 5, 7.5, 10 mg/kg | 3.7 | ||
This study | Systematic review | 89 | 39 | 50 | 1-15 mg/kg q2-6w | 2–6 |